DEF 14A: Pressure BioSciences Seeks Stockholder Approval for Director Election, Auditor Ratification, and Equity Incentive Plan

Pressure BioSciences is holding a special meeting to elect a director, ratify its auditor, approve a new equity incentive plan, and conduct an advisory vote on executive compensation.

Summary

• Pressure BioSciences, Inc. is soliciting proxies for a Special Meeting in Lieu of the Annual Meeting of Stockholders to be held on April 18, 2024.
• The meeting will address the election of one Class III Director, ratification of the appointment of MaloneBailey LLP as the independent registered public accounting firm for 2024, approval of the 2024 Equity Incentive Plan, and an advisory vote on executive compensation.
• Shareholders of record as of February 21, 2024, are entitled to vote.
• The Board of Directors recommends voting in favor of all proposals.
• The company has issued 25,740,123 shares of common stock as of the record date.
• The company has also issued 8,601 shares of Series AA Convertible Preferred Stock, 858 shares of Series BB Convertible Preferred Stock and 21 shares of Series CC Convertible Preferred Stock, which are not entitled to vote on any proposal to be presented at the Meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting information in a neutral and factual manner. The overall sentiment is moderately positive as it reflects the company's efforts to engage with shareholders and maintain good corporate governance.

Positives

• The Board is actively engaged in corporate governance, with all directors attending at least 80% of board meetings in 2023.
• The Audit Committee is composed of independent directors, ensuring oversight of financial reporting and controls.
• The company has a Code of Ethics for Senior Financial Officers, promoting ethical conduct.
• The company is seeking shareholder input on executive compensation through a non-binding advisory vote.

Risks

• The advisory vote on executive compensation could result in negative feedback from shareholders if they disapprove of the compensation packages.
• Failure to ratify the appointment of MaloneBailey LLP could necessitate a search for a new independent registered public accounting firm.
• If the number of shares of Common Stock present or represented and voting in favor of the approval of any of Proposal Nos. 1 through 4 is not sufficient to approve that proposal, we currently intend to move to adjourn the Meeting in order to enable our Board of Directors to solicit additional proxies for the approval of any of Proposal Nos. 1 through 4.

Future Outlook

The document outlines the matters to be voted on at the Special Meeting, which will influence the company's governance and executive compensation structure.

Management Comments

• Jeffrey N. Peterson, Chairman of the Board, cordially invites stockholders to attend the Special Meeting.
• The Board recommends that you vote in accordance with our Board's recommendations on all proposals.
• Richard T. Schumacher, Clerk, states that the notice is first being mailed to stockholders of the Company on or about February 29, 2024.

Industry Context

Proxy statements are standard practice for publicly traded companies, ensuring shareholders have the opportunity to vote on key decisions regarding the company's direction and governance.

Comparison to Industry Standards

• The director compensation structure, including quarterly stipends and committee fees, is typical for companies of similar size and stage of development.
• The use of equity incentive plans to attract and retain key employees is a common practice in the biotechnology industry.
• The company's approach to executive compensation, considering both corporate and individual goals, aligns with industry best practices.

Related Party Transactions

• Pressure BioSciences has a strategic product licensing, manufacturing, co-marketing, and collaborative research and development agreement with Target Discovery Inc. (TDI), a related party.
• Pressure BioSciences has a non-exclusive license agreement with TDI to grant the non-exclusive use of our pressure cycling technology.
• During the year ended December 31, 2022, we received short-term non-convertible loans of $958,100 from related parties and made payments of $315,300, for an ending balance of $634,885, which includes an unamortized debt discount of $7,915.

Stakeholder Impact

• Shareholders will have the opportunity to influence the company's direction through their votes on the proposals.
• Employees, officers, directors, consultants, and advisors may benefit from the 2024 Equity Incentive Plan.
• The outcome of the auditor ratification vote will impact the company's financial reporting and transparency.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Special Meeting on April 18, 2024, to address the listed proposals.
• The Board of Directors will implement the outcomes of the votes, including the election of the director and the approval of the equity incentive plan.

Key Dates

Keywords

proxy statement, stockholders, board of directors, equity incentive plan, executive compensation, director election, auditor ratification, corporate governance, Pressure BioSciences